152 related articles for article (PubMed ID: 10603626)
1. Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands.
Rutten-van Mölken MP; Postma MJ; Joore MA; Van Genugten ML; Leidl R; Jager JC
Respir Med; 1999 Nov; 93(11):779-87. PubMed ID: 10603626
[TBL] [Abstract][Full Text] [Related]
2. Active detection of chronic obstructive pulmonary disease and asthma in the general population. Results and economic consequences of the DIMCA program.
van den Boom G; van Schayck CP; van Möllen MP; Tirimanna PR; den Otter JJ; van Grunsven PM; Buitendijk MJ; van Herwaarden CL; van Weel C
Am J Respir Crit Care Med; 1998 Dec; 158(6):1730-8. PubMed ID: 9847260
[TBL] [Abstract][Full Text] [Related]
3. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands.
Feenstra TL; van Genugten ML; Hoogenveen RT; Wouters EF; Rutten-van Mölken MP
Am J Respir Crit Care Med; 2001 Aug; 164(4):590-6. PubMed ID: 11520721
[TBL] [Abstract][Full Text] [Related]
4. [Projections of future resource use and the costs of asthma and COPD in the Netherlands].
Hoogendoorn M; Feenstra TL; Rutten-van Mölken MP
Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1243-50. PubMed ID: 16796176
[TBL] [Abstract][Full Text] [Related]
5. The burden of asthma and chronic obstructive pulmonary disease: data from The Netherlands.
Rutten van-Mölken MP; Feenstra TL
Pharmacoeconomics; 2001; 19 Suppl 2():1-6. PubMed ID: 11700783
[TBL] [Abstract][Full Text] [Related]
6. A dynamic population model of disease progression in COPD.
Hoogendoorn M; Rutten-van Mölken MP; Hoogenveen RT; van Genugten ML; Buist AS; Wouters EF; Feenstra TL
Eur Respir J; 2005 Aug; 26(2):223-33. PubMed ID: 16055869
[TBL] [Abstract][Full Text] [Related]
7. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991.
Jacobson L; Hertzman P; Löfdahl CG; Skoogh BE; Lindgren B
Respir Med; 2000 Mar; 94(3):247-55. PubMed ID: 10783936
[TBL] [Abstract][Full Text] [Related]
8. Budesonide + formoterol delivered via Spiromax
Lewis A; Torvinen S; Dekhuijzen PNR; Chrystyn H; Melani A; Zöllner Y; Kolbe K; Watson AT; Blackney M; Plich A
Respir Med; 2017 Aug; 129():179-188. PubMed ID: 28732829
[TBL] [Abstract][Full Text] [Related]
9. The prevalence of COPD: using smoking rates to estimate disease frequency in the general population.
Stang P; Lydick E; Silberman C; Kempel A; Keating ET
Chest; 2000 May; 117(5 Suppl 2):354S-9S. PubMed ID: 10843976
[TBL] [Abstract][Full Text] [Related]
10. [Costs of illness for asthma and COPD in adults in Germany].
Kirsch F; Teuner CM; Menn P; Leidl R
Gesundheitswesen; 2013 Jul; 75(7):413-23. PubMed ID: 23553190
[TBL] [Abstract][Full Text] [Related]
11. Smoking prevalence and cessation characteristics among U.S. adults with and without COPD: findings from the 2011 Behavioral Risk Factor Surveillance System.
Schauer GL; Wheaton AG; Malarcher AM; Croft JB
COPD; 2014 Dec; 11(6):697-704. PubMed ID: 24841392
[TBL] [Abstract][Full Text] [Related]
12. Prevalence estimates of asthma or COPD from a health interview survey and from general practitioner registration: what's the difference?
Mohangoo AD; van der Linden MW; Schellevis FG; Raat H
Eur J Public Health; 2006 Feb; 16(1):101-5. PubMed ID: 16141304
[TBL] [Abstract][Full Text] [Related]
13. [Societal costs of asthma, COPD and respiratory allergy].
Suijkerbuijk AW; de Wit GA; Wijga AH; Heijmans M; Hoogendoorn M; Rutten-van Mölken M; Maurits EE; Hoogenveen RT; Feenstra TL
Ned Tijdschr Geneeskd; 2013; 157(46):A6562. PubMed ID: 24220178
[TBL] [Abstract][Full Text] [Related]
14. History of Asthma in Patients with Chronic Obstructive Pulmonary Disease. A Comparative Study of Economic Burden.
Sadatsafavi M; Tavakoli H; Kendzerska T; Gershon A; To T; Aaron SD; FitzGerald JM;
Ann Am Thorac Soc; 2016 Feb; 13(2):188-96. PubMed ID: 26599154
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology of chronic obstructive pulmonary disease (COPD).
Viegi G; Scognamiglio A; Baldacci S; Pistelli F; Carrozzi L
Respiration; 2001; 68(1):4-19. PubMed ID: 11223724
[TBL] [Abstract][Full Text] [Related]
16. A review of population studies from India to estimate national burden of chronic obstructive pulmonary disease and its association with smoking.
Jindal SK; Aggarwal AN; Gupta D
Indian J Chest Dis Allied Sci; 2001; 43(3):139-47. PubMed ID: 11529432
[TBL] [Abstract][Full Text] [Related]
17. Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus: A National Health System Perspective.
Cedillo S; Sicras-Mainar A; Jiménez-Ruiz CA; Fernández de Bobadilla J; Rejas-Gutiérrez J
Eur Addict Res; 2017; 23(1):7-18. PubMed ID: 27794567
[TBL] [Abstract][Full Text] [Related]
18. Economic burden from smoking-related diseases in Thailand.
Bundhamcharoen K; Aungkulanon S; Makka N; Shibuya K
Tob Control; 2016 Sep; 25(5):532-7. PubMed ID: 26427527
[TBL] [Abstract][Full Text] [Related]
19. Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone.
Gerhardsson de Verdier M; Andersson M; Kern DM; Zhou S; Tunceli O
Value Health; 2015 Sep; 18(6):759-66. PubMed ID: 26409602
[TBL] [Abstract][Full Text] [Related]
20. Chronic bronchitis and chronic obstructive pulmonary disease: Finnish National Guidelines for Prevention and Treatment 1998-2007.
Laitinen LA; Koskela K
Respir Med; 1999 May; 93(5):297-332. PubMed ID: 10464898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
